These novel medications , Semaglutide , represent a remarkable advancement in treating obesity and possibly other conditions . They all are grouped as GLP-1 pathway agonists , meaning they to emulate the endogenous GLP-1 peptide, boosting metabolic production and reducing appetite . While Retatru